Common Aminoglycosides and Platinum-Based Ototoxic Drugs: Cochlear/Vestibular Side Effects and Incidence

Robert M. DiSogra

doi:10.1055/s-0039-1684040

Seminars in Hearing, Table of Contents

Semin Hear 2019; 40(02): 104-107
DOI: 10.1055/s-0039-1684040

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Common Aminoglycosides and Platinum-Based Ototoxic Drugs: Cochlear/Vestibular Side Effects and Incidence

Robert M. DiSogra

¹School of Communication Disorders and Deafness, Kean University, Union, New Jersey

› Author Affiliations

Abstract

This is a reference chart that identifies 16 aminoglycoside antibiotics and platinum based drugs that could be cochleotoxic, vestibulotoxic or both. Using the most currently available data from published research from the National Library of Medicine's PubMed data base, incidence figures and risk factors are included in the chart along with the potential of permanence of reversibility of the impairment.

Keywords

Cochleotoxic - vestibulotoxic - aminoglycoside antibiotics

Full Text

References

References
1 Javadi MR, Abtahi B, Gholami K, Safari Moghadam B, Tabarsi P, Salamzadeh J. The incidence of amikacin ototoxicity in multidrug-resistant tuberculosis patients. Iran J Pharm Res 2011; 10 (04) 905-911
2 Fetoni AR, Ruggiero A, Lucidi D. , et al. Audiological monitoring in children treated with platinum chemotherapy. Audiol Neurotol 2016; 21 (04) 203-211
3 Clemens E, de Vries AC, Am Zehnhoff-Dinnesen A. , et al. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors. Pediatr Hematol Oncol 2017; 34 (02) 120-129
4 Brooks B, Knight K. Ototoxicity monitoring in children treated with platinum chemotherapy. Int J Audiol 2018; 57 (Suppl. 04) S34-S40
5 Musial-Bright L, Fengler R, Henze G, Hernáiz Driever P. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 2011; 27 (03) 407-413
6 Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol 2016; 2016: 1809394
7 Kobayashi H, Ohashi N, Watanabe Y, Mizukoshi K. Clinical features of cisplatin vestibulotoxicity and hearing loss. ORL J Otorhinolaryngol Relat Spec 1987; 49 (02) 67-72
8 Erythromycin and hearing loss. Available at: www.ehealthme.com/ds/erythromycin/hearing-loss . May 27, 2018
9 Agustí C, Ferrán F, Gea J, Picado C. Ototoxic reaction to erythromycin. Arch Intern Med 1991; 151 (02) 380
10 Matz GJ. The ototoxic effects of ethacrynic acid in man and animals. Laryngoscope 1976; 86 (08) 1065-1086
11 Elidan J, Lin J, Honrubia V. The effect of loop diuretics on the vestibular system. Assessment by recording the vestibular evoked response. Arch Otolaryngol Head Neck Surg 1986; 112 (08) 836-839
12 Rybak LP. Pathophysiology of furosemide ototoxicity. J Otolaryngol 1982; 11 (02) 127-133
13 Vestibular Disorders Association. Available at: https://vestibular.org/ototoxicity . Accessed 2018
14 Frymark T, Leech H, Mullen R, Schooling T, Venediktov R, Wang B. Evidence-based systematic review: drug-induced hearing loss – gentamicin. Available at: www.drugs.com/sfx/lasix-side-effects.html . Accessed 2010
15 Sequi Canet JM, Angelats Romero CM, Sequi Sabater JM, Miralles Torres A, Boronat Garcia M, Gomez Delgado M. Otoacoustic emissions in children treated with gentamicin in a secondary hospital. Acta Otorrinolaringol Esp 2018; 69 (05) 291-296
16 Sharma V, Bhagat S, Verma B, Singh R, Singh S. Audiological evaluation of patients taking kanamycin for multidrug resistant tuberculosis. Iran J Otorhinolaryngol 2016; 28 (86) 203-208
17 Winterstein AG, Liu W, Xu D, Antonelli PJ. Sensorineural hearing loss associated with neomycin eardrops and nonintact tympanic membranes. Otolaryngol Head Neck Surg 2013; 148 (02) 277-283
18 Professional guide for Neomycin and Polymyxin B. Available at: www.drugs.com/ppa/neomycin.html . Accessed 2018
19 American Medical Association. AMA Drug Evaluations. 3rd ed. Littleton, MA: PSG Publishing Co., Inc.; 1977: 759
20 Jarboe JK, Hallworth R. The effect of quinine on outer hair cell shape, compliance and force. Hear Res 1999; 132 (1-2): 43-50
21 Obasikene G, Adobamen P, Okundia P, Ogusi FO. Prevalence of ototoxicity in University of Benin Teaching Hospital, Benin city: a 5-year review. Niger J Clin Pract 2012; 15 (04) 453-457
22 Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007; 7: 5
23 Adeyemo AA, Oluwatosin O, Omotade OO. Study of streptomycin-induced ototoxicity: protocol for a longitudinal study. Springerplus 2016; 5 (01) 758
24 Bitner-Glindzicz M, Rahman S. Ototoxicity caused by aminoglycosides. BMJ 2007; 335 (7624(: 784-785
25 Matz GJ. Aminoglycoside ototoxicity. Am J Otolaryngol 1986; 7 (02) 117-119
26 Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 53 (02) 483-486
27 Lustig LR. . Drug-induced ototoxicity. Merck Manual; 2018 . Available at: www.merckmanuals.com/professional/ear,-nose,-and-throat-disorders/inner-ear-disorders/drug-induced-ototoxicity . Accessed February 28, 2019
28 Brummett RE. Drug-induced ototoxicity. Drugs 1980; 19 (06) 412-428